FOXC1 protein was present in 84% of serous ovarian cystadenomas and 66.7% of borderline cystadenomas, whereas its expression was observed in only 37.5% of adenocarcinomas, which suggests that FOXC1 is a better prognosis marker [39]. The gene discussed is FOXC1; the disease is adenocarcinoma.